Ann: Race investor briefing & updated presentation, page-309

A couple of references relevant for Pillar 3:

https://media.cellsignal.com/www/pdfs/science/pathways/m6a-rna.pdf
https://www.nature.com/articles/s41392-020-00450-x.pdf

Trying to work out:

1. The other regulator proteins they will most likely target
2. The non-cancer indications they will go after (to me key factors could be combination of unmet clinical need and market size)
3. For #1, #2 is there low-hanging fruit driven by their existing collaborations with UoN, UoW, CoH?
4. Opportunity size (tricky until we know more about #1, #2, #3)

For it to be meaningful for value (i.e. something concrete) in a transaction ... they must think they can hit the ground running.